Introduction {#Sec1}
============

Congestive heart failure (CHF) is a prevalent disease and a heavy burden for health-care systems \[[@CR1]\] as well as for the affected individual. The leading symptom is an impairment of exercise performance, limiting patients' functioning and quality of daily life. However, physical limitations in individuals with CHF are only partly explained by cardiac function \[[@CR2]\]. Comorbidities are prevalent in CHF \[[@CR3]\] and, with the aging of Western populations, will be even more so in the future. They are known to strongly influence the overall prognosis and health-care utilization \[[@CR4]\]. However, data are limited regarding the influence of comorbidities on signs and symptoms in CHF. Furthermore, most analyses dealing with the impact of comorbidities evaluated the influence of one single disease entity at a time. Dyspnea and a limitation in exercise capacity are usually the complaints in CHF \[[@CR5]\] that induce a specialist consultation to confirm a suspicion of CHF. They are the most important subjective parameters to evaluate the course of the disease in an individual. More than 50% of patients with the clinical syndrome of heart failure have a normal left ventricular ejection fraction \[[@CR6], [@CR7]\]. These cases can therefore be termed "heart failure with preserved ejection fraction" (or HFpEF) as compared to "heart failure with reduced ejection fraction" (or HFrEF). Although the overall prognosis in HFpEF is similarly grim as in HFrEF \[[@CR6], [@CR7]\], patients frequently die from non-cardiac causes and less often from heart failure than HFrEF patients \[[@CR8]--[@CR10]\]. Comorbidities are therefore believed to play a more important role in HFpEF than in HFrEF \[[@CR11]\]. Still, knowledge about the impact of such comorbidities on symptoms in HFpEF is even more limited than in HFrEF.

We therefore aimed to compare the frequency of 12 major comorbidities and their impact on NYHA class and SF-36 physical functioning (PF) score in a large nation-wide sample of CHF patients. We hypothesized that the impact of comorbidities would be higher in patients with HFpEF than with HFrEF.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

We performed a retrospective cross-sectional analysis of all patients who were screened for clinical trials performed within the framework of the German Competence Network Heart Failure (CNHF).

The CNHF is a government-sponsored nation-wide network consisting of infrastructure and scientific projects dedicated to improvement in efficiency and efficacy of research in CHF, quality of care for CHF patients, and educating the public about CHF (for details see Mehrhof et al. \[[@CR12].\] and ([www.ghfn.eu](http://www.ghfn.eu))). All trials within the CNHF comply with the declaration of Helsinki; the protocols were approved by the responsible ethics committees and all patients gave written informed consent. Diagnostic procedures within CNHF were performed according to standard operating procedures (SOP). For all clinical projects within the framework of CNHF, a harmonized basic clinical data set consisting of 190 items has been developed including echocardiographic parameters. Echocardiography was performed according to international guidelines transferred into CNHF SOPs. Data storage and analysis were performed at a central data management unit.

Within the basic data set, information was available on the following 12 major comorbidities that are typical for an elderly heart failure population \[[@CR4]\]: presence of coronary artery disease (CAD), peripheral arterial occlusive disease (PAOD) and cerebrovascular disease (i.e., history of stroke or transitory ischemic attack). These were classified according to medical history. Chronic obstructive pulmonary disease (COPD), diabetes mellitus, hypertension, hyperlipidemia and hyperuricemia were classified according to medical history or respective medication. Renal dysfunction (i.e., eGFR \<60 ml/min per m^2^; eGFR calculated by MDRD formula \[[@CR13]\]) and anemia (i.e., Hb \<12 or 13 g/dl for women or men, respectively) were classified according to history and pathological laboratory values at screening. Obesity was defined as a body mass index \>30 kg/m^2^; diagnosis of atrial fibrillation was based on baseline ECGs and therefore represents persistent or permanent atrial fibrillation only. NYHA functional class was assessed by screening physicians and quality of life by the SF-36 standard questionnaire \[[@CR14]\].

Patients {#Sec4}
--------

Data were assessed at the individual patient level at the screening visit for each trial and were pooled for this analysis across five interventional and six non-interventional trials (for details see Mehrhof et al. \[[@CR12]\]). Patients were classified as having CHF by experienced cardiologists at screening, and as having HFpEF when LV-EF was ≥50% or HFrEF when LV-EF was \<50% on baseline echocardiography.

Statistical analyses {#Sec5}
--------------------

Baseline data were presented as mean (standard deviation) for quantitative variables, and absolute number (%) for frequencies. The *t* test and Fisher's test were used for comparisons between groups for quantitative variables and frequencies, respectively.

The impact of different comorbidities on NYHA class was assessed by ordinal regression, adjusted for age, sex and CHF group (HFrEF or HFpEF). In preliminary analyses, the interaction term of the CHF group and comorbidity was included to examine whether the effects of the comorbidity on NYHA class in HFrEF and HFpEF patients should be considered to be of the same or different size. If the *p* value for interaction was ≥0.1, a common estimate of the odds ratio was presented. In case of a significant (*p* \< 0.05) or borderline (0.05 ≤ *p* \< 0.1) interaction term, homogeneity of the odds ratios was not assumed, and separate estimates in the HFrEF and HFpEF groups were computed.

The association between comorbidities on the SF-36 PF scale was analyzed in the same manner, using linear regression.

Multiple regression analyses (ordinal or linear, respectively) for NYHA class and SF-36 PF were performed, including all comorbidities as covariates for both groups. We also included into these analyses two echocardiographic measures: left ventricular ejection fraction (LV-EF) describing the severity of systolic dysfunction in HFrEF and left ventricular end-diastolic diameter (LVD\[ED\]) reflecting impaired ventricular filling in HFpEF. This allows weighing the impacts of ventricular dysfunction and comorbidities on symptoms and physical functioning against each other.

Based on the multiple regression models, areas under ROC curves for the prediction of NYHA classes III--IV and explained variances (*R*^2^) for the prediction of the SF-36 physical functioning scale were computed to illustrate the explanatory impact of comorbidities on top of sociodemography and echocardiographic parameters.

Results {#Sec6}
=======

Among 8,368 individuals screened for participation, 4,259 were identified with CHF. Of these, information was missing on LV-EF in 150, NYHA class in 25, both LV-EF and NYHA in 4, and age in 1 patient. Of 4,079 patients available for analysis, 2,785 (68%) had HFrEF and 1,294 (32%) had HFpEF. Out of these, 3,476 (85.2%) completed the SF-36 questionnaire. In multivariate logistic regression analysis including age, sex and CHF group as covariates, only age significantly predicted the completion of the SF-36 questionnaire.

HFpEF patients were older, more frequently female, had higher blood pressures and were less intensively treated with heart failure medications (Table [1](#Tab1){ref-type="table"}). They were also less symptomatic with a lower mean NYHA class and a lower number of CHF symptoms per patient with lower rates for all individual symptoms except peripheral edema (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). SF-36 PF score was higher in HFpEF.Table 1Clinical characteristicsHFrEF (*n* = 2,785)HFpEF (*n* = 1,294)*p* valueAge (years)63 ± 1467 ± 13\<0.001Female sex709 (25.5%)696 (53.8%)\<0.001Systolic blood pressure (mmHg)123 ± 20142 ± 24\<0.001Diastolic blood pressure (mmHg)73 ± 1281 ± 13\<0.001Heart rate (1/min)76 ± 1770 ± 14\<0.001Medication (n) ACEI/ARB2,458 (88.3%)790 (61.1%)\<0.001 Beta-blocker2,352 (84.5%)669 (51.7%)\<0.001 Diuretic2,213 (79.5%)680 (52.6%)\<0.001 Aldosterone antagonist1,290 (46.3%)61 (4.7%)\<0.001Signs and symptoms NYHA class2.4 ± 0.62.0 ± 0.6\<0.001 SF-36 physical functioning score49.6 ± 28.354.4 ± 27.7\<0.001 Dyspnea on exertion2,424 (87.0%)1,088 (84.1%)0.013 Dyspnea at rest327 (11.7%)88 (6.8%)\<0.001 Peripheral edema713 (25.6%)432 (33.4%)\<0.001 Neck vein distention187 (6.7%)31 (2.4%)\<0.001 Pulmonary rales317 (11.4%)52 (4.0%)\<0.001 Number of symptoms1.4 ± 1.01.3 ± 0.8\<0.001Echocardiography Left ventricular ejection fraction31.2 ± 9.462.0 ± 8.4n.a.\* End-diastolic LV diameter (mm)62.3 ± 10.148.2 ± 7.6\<0.001Comorbidities (n) Diabetes mellitus864 (31.0%)313 (24.2%)\<0.001 Hypertension1,709 (61.4%)1,014 (78.4%)\<0.001 Hyperlipidemia1,638 (58.8%)699 (54.0%)0.004 Hyperuricemia1,086 (39.0%)252 (19.5%)\<0.001 Coronary artery disease1,286 (46.2%)405 (31.3%)\<0.001 Renal dysfunction962 (34.5%)341 (26.4%)\<0.001 Anemia610 (21.9%)183 (14.1%)\<0.001 Obesity746 (26.8%)486 (37.6%)\<0.001 COPD421 (15.1%)163 (12.6%)0.035 Peripheral artery disease292 (10.5%)98 (7.6%)\<0.001 Cerebrovascular disease308 (11.1%)117 (9.0%)\<0.001 Atrial fibrillation581 (20.9%)124 (9.6%)\<0.001 Number of comorbidities3.8 ± 2.13.2 ± 1.9\<0.001\* Different by definition of groupsFig. 1Distribution across **a** NYHA grades and **b** individual number of CHF symptoms in patients with HFrEF (*open columns*) or HFpEF (*filled columns*)

Only hypertension and obesity were more frequent in HFpEF, while all other comorbidities were observed more frequently in HFrEF patients. Seven comorbidities did not show an interaction with CHF group in ordinal regression analysis, i.e., their influence on NYHA class and SF-36 PFS was similar in both groups (Table [2](#Tab2){ref-type="table"}). All these comorbidities had a highly significant impact on patients' symptoms by increasing NYHA class and reducing SF-36 PF score, with COPD and anemia showing the strongest associations. The remaining five comorbidities behaved differently in HFpEF and HFrEF: In HFrEF, hypertension and hyperlipidemia were associated with a better NYHA class, while the latter impacted on the NYHA class negatively in HFpEF and was also associated with a worse SF-36 PF in these patients. CAD had a negative effect on NYHA class in HFpEF only and its association with lower SF-36 PF was significantly stronger than that observed in HFrEF patients. Similarly, a negative impact of PAOD on NYHA class and SF-36 PF was significantly stronger in HFpEF compared with HFrEF. Obesity significantly increased NYHA class in HFpEF only, while there was no significant difference in its (negative) impact on SF-36 PF in both CHF groups.Table 2Impact on NYHA class and SF-36 physical functioning scale of comorbidities, corrected for age and sexComorbidityImpact on NYHA classImpact on SF-36 PFSOdds ratio (95% CI)*p* valueCoefficient (95% CI)*p* valueComorbidities without significant interaction COPD  Interaction0.180.10  Common estimate1.82 (1.54; 2.15)\<0.001−12.79 (−10.27; −15.30)\<0.001 Cerebrovascular disease  Interaction1.000.43  Common estimate1.49 (1.26; 1.77)\<0.001−8.27 (−5.35; −11.18)\<0.001 Atrial fibrillation  Interaction0.100.73  Common estimate1.59 (1.37; 1.83)\<0.001−6.14 (−3.74; −8.55)\<0.001 Diabetes  Interaction0.790.09  Common estimate1.26 (1.11; 1.45)\<0.001−5.82 (−3.82; −7.83)\<0.001 Renal dysfunction  Interaction0.600.16  Common estimate1.51 (1.31; 1.73)\<0.001−7.41 (−5.38; −9.44)\<0.001 Anemia  Interaction0.360.25  Common estimate1.77 (1.51; 2.07)\<0.001−9.74 (−7.46; −12.02)\<0.001 Hyperuricemia  Interaction0.580.10  Common estimate1.60 (1.40; 1.82)\<0.001−6.53 (−4.61; 8.45)\<0.001Comorbidities with significant interaction Obesity  Interaction0.010.68  HFrEF subgroup1.10 (0.93; 1.30)0.26  HFpEF subgroup1.53 (1.22; 1.92)\<0.001  Common estimate−4.35 (−2.39; −6.30)\<0.001 Hypertension  Interaction0.060.02  HFrEF subgroup0.75 (0.64; 0.88)0.0010.28 (−2.09; 2.66)0.82  HFpEF subgroup0.89 (0.66; 1.18)0.41−4.6 (−0.65; −8.61)0.02 Hyperlipidemia  Interaction\<0.001\<0.001  HFrEF subgroup0.75 (0.65; 0.87)\<0.0011.82 (−0.41; 4.04)0.11  HFpEF subgroup1.38 (1.11; 1.73)0.005−6.28 (3.16; 9.40)\<0.001 Coronary artery disease  Interaction0.0010.001  HFrEF subgroup0.94 (0.80; 1.10)0.40−5.62 (−3.24; −7.99)\<0.001  HFpEF subgroup1.71 (1.33; 2.19)\<0.001−12.01 (−8.59; −15.42)\<0.001 Peripheral artery disease  Interaction0.020.04  HFrEF subgroup1.23 (0.97; 1.56)0.083−10.70 (−7.14; −14.26)\<0.001  HFpEF subgroup1.94 (1.28; 2.93)0.002−17.73 (−11.94; −23.52)\<0.001Separate estimates are given for HFrEF and HFpEF subgroups when the *p* value for interaction of comorbidity and ventricular function is significant (\<0.05) or borderline (\<0.1)

In multivariate analyses, hyperuricemia, renal dysfunction, anemia, COPD, cerebrovascular disease and atrial fibrillation retained their significantly negative impact on NYHA class in HFrEF, while hypertension and hyperlipidemia retained their protective effect (Fig. [2](#Fig2){ref-type="fig"}a). The strength of association for the negatively influencing comorbidities was similar to that of a reduction in LV-EF of 10% (which corresponds to a quartile of the distribution for this parameter in our cohort), with widely overlapping confidence intervals. In HFpEF, only CAD, anemia, obesity, COPD and atrial fibrillation had a significantly negative effect in multivariate ordinal regression analysis, although wider confidence intervals illustrated the lower statistical power to show influencing factors due to the lower subject number in this group. The effect of these comorbidities appeared to be much stronger than that of an LVD (ED) lowered by 5 mm (again corresponding to a quartile in our cohort), the most strongly associated parameter on routine echocardiography in this patient group. SF-36 PF score was negatively affected in HFrEF by all comorbidities except for diabetes, hypertension and hyperlipidemia, with the last two again showing a protective effect with regard to this parameter (Fig. [2](#Fig2){ref-type="fig"}b). The effects tended to be stronger than that of an LV-EF reduction. In HFpEF, hyperuricemia, CAD, renal dysfunction, anemia, obesity, COPD, PAOD and atrial fibrillation were associated with lower SF-36 PF score. Again, the effect of reduced LVD (ED) was significant but weak in comparison with comorbidities. LV-EF had no significant effect on HFpEF and the same held true for LVD (ED) in HFrEF.Fig. 2Odds ratios in multivariate analyses for **a** higher NYHA class and **b** SF-36 physical functioning score in HFrEF or HFpEF

Accordingly, adding both echocardiographic variables as covariates improved the prediction of NYHA classes III or IV in HFrEF, derived from the multivariate regression model, while AUC remained virtually unchanged in HFpEF (Fig. [3](#Fig3){ref-type="fig"}a). Expansion of the set of covariates for all comorbidities further improved the AUC in HFrEF to an extent similar to that provided by the addition of the echocardiographic variables. However, in HFpEF, the increase in AUC was much larger (+0.100 vs. +0.029), resulting in a similar AUC as in HFrEF for the final multivariate model that included all covariates, with a relatively larger share supplied by comorbidities in HFpEF.Fig. 3**a** AUC to predict higher NYHA class and **b***r*^2^ of multivariate linear model for SF-36 physical functioning score according to the set of covariates used for model building

In HFpEF, considerably more of the overall variability in SF-36 PF score was explained by sex and age only compared with HFrEF (Fig. [3](#Fig3){ref-type="fig"}b). Again, adding echocardiographic variables did not improve the multivariate model in HFpEF, while some improvement was noted for HFrEF, and the inclusion of all comorbidities further improved *r*^2^ by 7.6%. In HFpEF, comorbidities added 12.1% and thereby approximately doubled the explained variance, resulting in an *r*^2^ of 25.1%. The variance explained by comorbidities was therefore 1.59-fold higher in HFpEF than in HFrEF. The overall explained variance of SF-36 PF in HFpEF by sex, age, echocardiographic variables and comorbidities was 1.49-fold larger than in HFrEF, even though the echocardiographic variables had no impact on *r*^2^ in HFpEF.

Discussion {#Sec7}
==========

To our knowledge, our analysis is the first to evaluate the relative impact of multiple comorbidities on physical function in CHF in general, and in HFpEF and HFrEF in particular.

We find that patients with HFpEF are significantly less symptomatic than those with HFrEF. Of this lower CHF symptom load in absolute terms, a relatively larger part is explained by comorbidities, leaving a smaller fraction to be explained by heart failure itself (or possibly other factors). This is in spite of higher frequencies for most of the major comorbidities investigated and a higher number of comorbidities per patient in HFrEF.

CHF is a disease primarily of the elderly \[[@CR1]\]; comorbidities are prevalent in these patients \[[@CR4]\] and will be more so in the future due to an aging population \[[@CR15]\]. At the same time, specialization and subspecialization continues to be on the rise \[[@CR16], [@CR17]\], resulting in a strong focus of different specialists on individual diseases from their respective area of expertise, which may in turn compromise the care for other comorbidities \[[@CR18]\]. It has previously been shown that comorbidities have an impact on hospitalizations and mortality in patients with CHF \[[@CR4], [@CR19]\]. Our data complement this report, as we find a significant impact on patients' physical impairment in a large and diverse CHF population from observational as well as interventional trials with a harmonized basic data set. Comorbidities are therefore associated with relevant suffering in daily life in patients with CHF. At the same time, they strongly influence the main symptom that leads to a CHF-oriented diagnostic workup and is used to judge the course of disease and success of physicians' interventions. This observation may appear to be obvious and intuitive. However, if that is so, the above-mentioned trends in the organization of medical care might consequentially be considered suboptimal and counterintuitive.

All individual comorbidities had a significant impact on physical impairment in at least one of both heart failure groups. Several of these (such as COPD, history of stroke, atrial fibrillation, anemia or diabetes) generally limit exercise capacity by themselves, even in patients without CHF \[[@CR20]--[@CR23]\]. Others (like renal dysfunction or hyperuricemia) may in fact rather be indicators of more advanced and therefore more symptomatic CHF \[[@CR24], [@CR25]\]. Similarly, the association of hypertension and hyperlipidemia with a lower NYHA class in HFrEF may be due to the phenomenon of reverse epidemiology, i.e., the association of low blood pressure and lower lipid levels with an adverse prognosis and more advanced disease \[[@CR26]\]. Such an effect was not detectable for hypertension in HFpEF, and hyperlipidemia actually worsened NYHA class and SF-36 PF score. This differential impact on physical function contrasts with a recent report that showed a similar impact of hyperlipidemia and hypertension on prognosis in HFrEF as compared to HFpEF. Further studies will be needed to better understand the associations of comorbidities with symptom burden and prognosis in HFpEF patients \[[@CR26]\]. Hypertension may have a stronger negative impact on HFpEF due to ventriculo-vascular coupling \[[@CR27]\] and because it is a key factor for the development of left ventricular hypertrophy \[[@CR28]\] and diastolic dysfunction \[[@CR29]\]. Alternatively, the reverse association of low blood pressures with advanced disease may be less pronounced in HFpEF, an explanation that would also be in concordance with the overall lower symptom load, indicating a less advanced disease stage in our HFpEF group. This alternative explanation could also account for the differential impact of obesity. While this comorbidity would be expected to lead to worse physical functioning, as observed in our HFpEF group, this effect has likely been offset by reverse epidemiology in the HFrEF group, leading to a neutral impact on the NYHA class. The more pronounced influence of PAOD may be indicative of the relevance of ventriculo-vascular coupling for the development of HFpEF \[[@CR27], [@CR30]\].

Why should the overall effect of comorbidities on physical function be greater in HFpEF than in HFrEF patients, as observed in our analysis?

Patients with HFpEF are a heterogeneous group. While the presence of a lowered LV-EF adds some cardio-specificity to the clinical diagnosis of CHF, its absence does not. HFpEF therefore by principle will be much less specific for cardiac abnormalities as the underlying pathology for the clinical picture of heart failure. Consequentially, basing HFpEF exclusively on the clinical picture and the absence of major abnormalities in systolic function will lead to a higher number of cases falsely attributed to cardiac abnormalities \[[@CR31]\]. It is likely that some of these cases will have non-cardiac comorbidities as a main reason for reduced physical function.

It is also possible that comorbidities have a relatively higher impact on physical impairment in patients with true CHF due to cardiac (mainly diastolic) dysfunction with normal ejection fraction. This would suggest that diastolic dysfunction by itself would have a smaller effect on physical function than relevant systolic dysfunction (which is usually accompanied by some degree of diastolic function and in that sense is additive). Although the similarities in morbidity and mortality \[[@CR6], [@CR7]\] as well as health-care utilization \[[@CR32]\] between HFpEF and HFrEF may seem to argue against this, adverse prognosis in HFpEF has been reported to be associated in a large part with non-CHF events \[[@CR8]--[@CR10]\] and a differential influence of gender has been described \[[@CR33]\]. Further supporting this hypothesis is the fact that the echocardiographic variable most strongly associated with physical function in each group had a much stronger effect in HFrEF than in HFpEF. Cardiac abnormalities in HFpEF may therefore bear a smaller part of adverse prognosis and, as we show here, of impairment in physical function.

Our results strongly support two major calls to researchers and physicians dealing with heart failure patients: Firstly, a diagnosis of HFpEF must not be based on the absence of systolic abnormalities, but rather on the presence of non-systolic cardiac abnormalities. Otherwise, HFpEF populations will by conception include a larger number of non-cardiac etiologies for impaired physical function, making clinical research aimed at specific treatments for HFpEF challenging (and some would argue, impossible) \[[@CR31], [@CR34]\].

Secondly, caring for patients with CHF must include a strong focus on the diagnosis and treatment of comorbidities, because patients' suffering can only be partly addressed by treating their cardiac abnormalities only.

Some limitations of our analysis have to be addressed. Although we were limited in our analysis to a certain set of comorbidities, several other diseases that were not assessed in all of the studies included may also have an impact on physical function in heart failure patients (e.g., sleep-disordered breathing, depression, cognitive dysfunction, thyroid disorders, osteoporosis). We only had a basic set of echocardiographic data to include in our analysis. Including more recent markers of diastolic function might well have shown a stronger effect on physical function. However, smaller left ventricular end-diastolic dimensions have been shown to be characteristic of patients with HFpEF \[[@CR27], [@CR35]\] and were significantly associated with lower NYHA class in our cohort. Some of the evidence we present is of an indirect nature. A direct estimate of the impact of HFrEF or HFpEF itself on physical function in comparison with a non-CHF population would be most interesting, but cannot be derived from our data set. The diagnosis of comorbidities was largely history based and therefore suboptimal. However, we assume that such an approach will lead to under- rather than overdiagnosis and more cases of e.g., COPD, CAD or (paroxysmal) atrial fibrillation would have been revealed by more intensive diagnostic testing, increasing the relative impact of comorbidities on physical function. Similarly, a confirmation of our findings in an unselected patient population will be necessary. Because such a population will be older and more comorbid, a different impact of comorbidities cannot be excluded.

Conclusion {#Sec8}
==========

Comorbidities have a significant impact on NYHA class and SF-36 PF in HFrEF as well as in HFpEF. The influence of individual comorbidities is different in HFrEF as compared to HFpEF. The overall impact of comorbidities is higher in HFpEF than in HFrEF. This implies that comorbidities should play a larger role in the differential diagnosis of patients with exertional dyspnea and preserved ejection fraction. Focusing treatment on comorbidities may be more beneficial in HFpEF than in HFrEF.
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